Molecular and Steroid hormones, Neurotensin and Tumor Progression INSERM UPMC Cdr Saint-Antoine Eq 7, Paris, France Neurotensin (NT)-polyplex is a nonviral system for the targeted gene delivery to cells that express and internalize the high-affinity NT receptor (NTSR1). In hemiparkinsonian rats, we previously demonstrated the morphological and functional recovery from dopaminergic neurodegeneration using the NT-polyplex as a vehicle to transfect a neurotrophic gene. The main objective of this work was to demonstrate the feasibility of NT-polyplex to transfect reporter or therapeutic genes into neuroblastoma tumors through the blood stream or by intratumoral injection. N1E-115 cells known to express NTSR1 were allografted into athymic mice to generate the neuroblastoma tumor model. Both routes of administration allowed the NT-polyplex to reach and transfect tumoral cells. A low transgene expression was also detected in intestinal tract cells only after the injection into the blood stream. The transfection of the thymidine kinase (HSVTK) suicide gene followed by ganciclovir (GCV) treatment decreased the size and weight of neuroblastoma tumors by 30-50% and increased apoptosis compared to controls. This study shows the potential of the NTpolyplex as specific gene-transfer system for NTSR1 cancer cells.
Introduction
The neurotensin (NT)-polyplex is an efficient and specific gene delivery system for cells bearing the high-affinity NT receptor (NTSR1). 1, 2 This nonviral system consists of poly-L-lysine, NT, a fusogenic peptide (FP), a karyophilic peptide (KP) and a plasmid encompassing the coding sequence for a protein of interest (transgene). The components of the NT-polyplex allow the transgene to enter the cells, carry the transgene toward the cytosol and reach the cell nucleus. The cationic poly-L-lysine binds to the anionic plasmid DNA (pDNA) by electrostatic charges and compacts pDNA into a toroidal nanoparticle. 3 The tridecapeptide NT is the natural ligand of NTSR1 4 that on its activation causes NT-polyplex endocytosis. 2, 5 The FP (22 amino acids) is the pH-sensitive HA2-fusion domain from the influenza virus hemagglutinin known to cause membrane fusion and leakage of a lipid bilayer in endosomes. 6 This peptide is used to prevent pDNA degradation in the acidic endosomes. 7, 8 The KP (20 amino acids) is the potent nuclear location signal of the SV40 capsid protein Vp1 9 that is used in the NT-polyplex for an efficient targeting of pDNA to the cell nucleus. 8 These features of the NTpolyplex lead to an efficient gene transfection (450%) in cultured cells and in animals 3, 8 and a long-lasting transgene expression in animals (43 months). 8 The first use of the NT-polyplex in gene therapy was the transfection of the GDNF gene in nigral dopaminergic neurons in an animal model of Parkinson's disease, because these neurons express 4, 10 and internalize NTSR1. 5, 8, 11 The efficacy of the NT-polyplex is supported by the morphological and functional recovery from dopaminergic neurodegeneration in experimental hemiparkinsonism. 12 The neuroblastoma, an embryonic tumor derived from the neural crest, is the second most common solid tumor in childhood, 13 with invasion of locoregional nodes and distant metastasis in approximately 75% of cases in children older than 1 year. 14 In spite of the progress in medical and surgical treatments, long-term survival remains poor. Chemotherapy and radiotherapy have a limited impact on survival either when used as an adjuvant treatment after surgery or as a primary treatment in metastatic subjects because of the infiltrative ability, drug resistance, and morbidity of the cancerous cells. 14 The lack of a successful treatment in the advanced stage of the disease 15 has led to the pursuit of new therapeutic strategies, such as gene therapy. The NTpolyplex could be a specific tool to transfer therapeutic genes to neuroblastoma tumors because several human cell lines express NTSR1. 16, 17 In this work, the murine neuroblastoma N1E-115 cell line, which has been efficiently transfected by NT-polyplex in culture 1, 2, 8 because they overexpressed the NTSR1, 18 was allografted in athymic mice to develop an animal model of a neuroblastoma tumor. We hypothesized that the NTpolyplex will be able to transfer genes into neuroblastoma tumor cells after its injection into the tumor or through the blood stream. As a therapeutic gene, we used the herpes simplex virus thymidine kinase (HSVTK) gene ganciclovir (GCV) system because it is one of the most efficient approaches to cause cell death in active mitotic cells. 19 The expressed HSVTK and the endogenous kinase phosphorylate GCV, which is converted into an active and abnormal triphosphate purine analog. 20 Its insertion in elongating DNA by cellular DNA polymerases causes chain termination and cell death by apoptosis. 21, 22 After 11 days of tumor evolution, an NT-polyplex containing the plasmid pORF-HSVTK coding for HSVTK was injected into the retro-ophthalmic vein (systemic transfection) or into the tumor (intratumoral transfection), which was followed by a daily GCV treatment. Our results showed the ability of the NT-polyplex to transfect reporter genes specifically to tumoral cells after the intratumoral or systemic transfection. The therapeutic effect of the HSVTK-gene transfection and GCV treatment was the significant decrease of the growth of the neuroblastoma tumor. Our data claim is for the development of a gene-therapy strategy using the NT-polyplex for NTSR1-expressing cancer cells.
Materials and methods

Synthesis of the NT-carrier and polyplexes
The detailed procedure of NT-carrier synthesis and of NT-polyplex formation at an optimum molar ratio and its biophysical properties are reported in reference. 3 Briefly, NT (Sigma Co., Saint Louis, MO) and FP (GLFEAIAE-FIEGGWEGLIEGCAKKK; purity 490%; SynPep Corp., Dublin, CA) were cross-linked with poly-L-lysine (48 kDa mean molecular mass) using LC-SPDP as the cross-linker.
2 Suitable gel-filtration chromatography was used to purify the SPDP-derivatives and the NT-SPDP-(FP-SPDP)-poly-L-lysine conjugate, the NT-carrier. This conjugate was concentrated to 1 ml, further dialyzed against phosphate-buffered saline solution, pH 7.4, (PBS) and sterilized by filtration. The NT-polyplexes were made in Dulbecco's modified Eagle's medium (DMEM; Gibco, Invitrogen Corporation, Grand Island, NY) by electrostatically binding the mutant Vp1 SV40 KP (MAPTKRKGSCPGAAPNKPK; 90% purity; SynPep Corp.) to pDNA. 8 Retention and retardation microassays 3, 8 were used to determine the optimum molar ratios 
Cell culture
Wild-type N1E-115 cells (ATCC, Rockville, MD) were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin streptomycin (100 mg ml
À1
). GFP-NTS1-N1E-115 cells genetically engineered to express the fusion protein NTSR1 receptor with the green fluorescent protein (GFP) were cultured in DMEM supplemented with 10% FBS and 1 mg ml À1 Geneticin (G418; Sigma Co.) 23 for 2 weeks before being allografted.
Murine neuroblastoma model Athymic 3-month-old Nu-Nu male mice (Charles River Laboratories; Wilmington, MA) were subcutaneously injected with 2 Â 10 6 N1E-115 cells in the interscapular region. Animals were maintained at 23 1C in sterile boxes with water and food ad libitum and under 12-h light-dark periods. To avoid interference with vital functions by tumor growth and to minimize animal suffering, the study was ended three weeks after grafting. All procedures were in accordance with the Mexican legislation (NOM-062-ZOO-1999; SAGARPA) based on the Guide for the Care and Use of Laboratory Animals, NRC. The CINVES-TAV Committee for animal care and use (IACUC) approved and supervised our experimental procedures (authorization no. 0272-05).
For injections into tumors, the animals were deeply anesthetized with a mixture of ketamine-xylazine (5:1 mg kg À1 of body weight, i.p.; Pisa Agropecuaria, SA de CV, Mexico). A micropump (model MD1001; Bioanalytical System Inc., West Lafayette, IN) was used to inject 300 ml of NT-polyplex into a neuroblastoma tumor at a flow rate of 10 ml min
. For intravenous injections, 300 ml of NT-polyplex solution was injected in a bolus dose into the retroophthalmic vein using an insulin syringe (27 g Â 13 mm).
Internalization assays
The plasmids pDsRed2-N1 and pORF-HSVTK were labeled with propidium iodide (10 mM) before their use to form the NT-polyplex as we reported previously. 3, 8 The labeled NT-polyplex was immediately injected. The animals, under deep general anesthesia, were transcardially perfused with 50 ml of PBS and with 50 ml of the fixative (4% paraformaldehyde in PBS) 6 h after the injections. The dissected tumors were maintained in 30% sucrose solution for 36 h at 4 1C and then sectioned into 12-mm slices using a CM1100 Leica cryostat (Leica Microsystem, Nussloch, Germany). The tissue slices were mounted on glass slides and covered using Vectashield (Vector Laboratories Inc., Burlingame, CA).
The fluorescence within the cells were observed with a TCS SP2 Leica confocal microscope (Leica Microsystems) at excitation-emission wavelengths of 488-522 nm for GFP (green channel) and 568-585 nm for propidium iodide (red channel).
Expression of reporter genes
The plasmid pDsRed2-N1 was transfected with either the NT-polyplex or an untargeted NT-polyplex (n ¼ 3 animals per condition). The KP-plasmid complex (n ¼ 6) was used as an additional control. The expression of RFP was observed in 12-mm tumor slices counterstained with 1 mM Hoechst 33258 (Sigma Co.) 3 days after transfections. The fluorescence within the cells was observed with a Leica DMIRE2 microscope (Leica Microsystem, Wetzlar, Germany) using Â 20 and Â 40 objectives and the filters A for Hoechst 33258-nuclear staining (blue) and TX2 for RFP (red). Images were digitalized with a Leica DC300F camera (Leica Microsystems) and processed using the fluorescence workstation Leica FW4000, version V1.2.1 (Leica Microsystems Vertrieb GmbH, Bensheim, Germany).
The plasmids pORF-Luc or pORF-empty were transfected by NT-polyplex. Other controls for intratumoral transfection were the KP-pDNA complex, the untargeted polyplex, or the NT-polyplex in the presence of 1 mM SR 48692, a synthetic NT competitive antagonist. Animals were killed 24 h after transfection to obtain the tumor and the organs; brain, lung, heart, liver, pancreas, stomach, gut, colon and kidneys, which were immediately immersed in cold PBS. These organs were homogenized in the lysis buffer (1 mM DTT, 10% NP40 in Brasier's buffer) using a polytron (Brinkman Instruments Inc., Luzern, Switzerland). The luciferase expression was measured in homogenates using a T-20/20 model Luminismeter (Turner Designs Instruments, Sunny Valley, CA) according to the Brasier's method. 24 Values of Luc luminescence were normalized to mg protein, which was determined using the Coomassie Plus-The Better Bradford Assay Kit (Pierce, Rockford, IL) and bovine albumin as standard.
Effect of a suicide gene transfection
The plasmids pORF-HSVTK and pORF-empty were transfected with the NT-polyplex. Other controls for intratumoral transfection were (1) the injection of NTpolyplex carrying the empty plasmid (pORF) and GCV treatment, (2) the injection of an untargeted polyplex carrying the pORF-HSVTK and GCV treatment and (3) the injection of NT-polyplex carrying the pORF-HSVTK without GCV treatment. The GCV treatment (75 mg kg À1 of body weight, ip) was begun 24 h after the transfection and repeated daily for a week. An additional dose of NTpolyplex was given each second day. Another control was the intraperitoneal injection of saline solution after transfection of pORF-HSVTK. Daily measurements of tumor size (length, width and height) were done through the skin with a vernier device.
Cleaved caspase-3 immunostainings
On completion of the experiment, the animals were killed under deep anesthesia, perfused transcardially with 50 ml of PBS and then fixed with 50 ml of 4% paraformaldehyde. The tumors were sectioned into 20-mm slices that were incubated with 10% horse serum in PBS-0.1% Triton for 120 min at room temperature. After the blockage of unspecific binding sites, the slices were incubated with a rabbit cleaved caspase-3 antibody (1:600; Cell Signaling Technology Inc., Danvers, MA) at 4 1C overnight. For immunofluorescence, the slices were incubated with a goat anti-rabbit IgG-FITC (1:200; Sigma-Aldrich Co., St Louis, MO) for 2 h at room temperature. Finally, the slices were washed with PBS thrice, counterstained with Hoechst 33258 (1 mM) and mounted on glass slides with Vectashield. The fluorescence within the cells was observed with a Leica DMIRE2 microscope (Leica Microsystem) using the filters A for Hoechst 33258-nuclear staining (blue) and K3 for FITC (green). Images were digitalized with a Leica DC300F camera (Leica Microsystems) and processed using the fluorescence workstation Leica FW4000, version V1.2.1 (Leica Microsystems Vertrieb GmbH). For immunohistochemistry, the slices were incubated with a goat antirabbit IgG-secondary antibody biotinylated (H þ L) (1:300 dilution; Vector Laboratories Inc.) for 2 h at room temperature. This was followed after rinsing by using the kit avidin-biotin-peroxidase complex (Vector Laboratories Inc.) for 20 min at room temperature. The peroxidase reaction was developed by immersion in a freshly prepared solution of 0.02% 3,3 0 -diaminobenzidine (Sigma Co.). The slices were counterstained with cresyl violet stain. Cleaved caspase-3 immunoreactivity was analyzed with the Leica DMIRE2 microscope. The images were digitalized with a Leica DC300F camera and analyzed with the Leica FW4000 workstation, version V1.2.1 (Leica Microsystems Vertrieb GmbH).
Statistical analysis
All values are expressed as the mean±s.d. and difference between groups were analyzed with one-way ANOVA test and Bonferroni's post hoc test. The unpaired Student's t-test showed the difference between pairs of group's means. All the statistical analyses were made in the version 4 of GraphPad Prism (GraphPad Software Inc., San Diego, CA). A significant difference was assumed at least Po0.05.
Results
NT-polyplex internalization in neuroblastoma cells
The N1E-115-NTSR1-GFP cells were allografted into mice. After 11 days of growth, we verified that the NTpolyplex was internalized by tumoral cells after its intratumoral or systemic transfection. Before injection, the NT-polyplex was labeled with propidium iodide. Both horizontal and vertical optical sections of confocal microscopy showed the propidium iodide fluorescence within the GFP-fluorescent cells at 6 h after the intratumoral (Figures 1b and e) or systemic transfection ( Figures  1c and f) . In contrast, no propidium iodide fluorescence was observed within the GFP-fluorescent cells when either an untargeted polyplex lacking the ligand NT (Figures 1a and d) or a propidium iodide-labeled KPpDNA complex (data not shown) were injected into the tumor or through the blood stream. These results demonstrate that the NT-polyplex was transfected specifically through the NT pathway into neuroblastoma tumoral cells after its intratumoral or systemic injection.
NT-polyplex-mediated transgene expression
Wild-type N1E-115 cells were allografted into mice. After 11 days of tumoral growth, NT-polyplex complexed with a plasmid expressing RFP, pDsRed2N-1 was injected into the tumor or through the blood stream. RFP expression and Hoechst 33258-counterstained cells were determined in a representative slice of each section (proximal, medial and distal) of three independent tumors, and in each experimental condition. The images shown in Figures 2 d-i were selected to show the transfection efficiency. RFP was detected 72-h after transfection regardless of the transfection route (Figures 2e and h) . Transgene expression was mainly found in areas near the injection site (in the middle of the tumor) after intratumoral transfection (Figures 3d-f) , where the expression efficiency was 12 ± 3% (Figure 2f) as expressed as the number of RFP-expressing cells out of the total Hoechst 33258-counterstained cells counted in random fields using a Â 20 objective (n ¼ 10 fields). In contrast, RFP expression was mainly found in areas of the tumor base after systemic transfection (Figures 3g-i) where the expression efficiency was 8 ± 2%, n ¼ 10 fields (Figure 2i) . As a control, no RFP expression was observed in the cells when an untargeted polyplex was injected into the tumor (Figures 2a-c and 3a-c) or through the blood stream (data not shown). Another negative control was the intratumoral or systemic transfection of KP-pDNA complex (data not shown). By using the NT-polyplex complexed with the plasmid expressing luciferase (Luc), pORF-Luc, we estimated the level of the transgene expression at 24 h after the intratumoral or systemic transfection of NT-polyplex (Figure 4) . The relative light units (RLU) per mg of protein in tumors injected with pORF-Luc (n ¼ 7) were significantly higher than RLUs in control tumors. The controls for the intratumoral transfection were the injection of (1) the empty plasmid (n ¼ 6), (2) the KPpDNA complex (n ¼ 4), (3) the untargeted polyplex (n ¼ 4) or (4) the NT-polyplex in the presence of 1 mM SR 48692 (n ¼ 4), a synthetic NT competitive antagonist (Figure 4) . The systemic transfection with pORF-Luc (n ¼ 4) also showed higher luciferase expression than the transfection with the empty plasmid (n ¼ 6). Luciferase expression after the intratumoral transfection was greater than that after the systemic transfection. The control positive was the transfection in vitro with the NT-polyplex in N1E-115 cells, whose value was 4893 ± 1134 RLU per mg of protein (data not shown).
The results show the ability of NT-polyplex to provide reporter gene expression in neuroblastoma cells allografted into athymic mice after its intratumoral or systemic transfection.
Effect of HSVTK gene transfection on tumor growth
We explored the ability of NT-polyplex to transfect a suicide gene into the tumor cells and consequently to regulate the growth of the tumor. For this purpose, NT-polyplex carrying the plasmid pORF-HSVTK was injected into the tumor or through the blood stream and then treated with the prodrug GCV (75 mg kg À1 of body weight).
The growth rate of the tumors in animals with an intratumoral transfection of pORF-HSVTK and treated with GCV (n ¼ 9) was significantly slower than that in control animals (Figure 5a ). At the end of the experiment, the weight of tumors transfected with the HSVTK gene was 38% less than that of control tumors (Figure 5b ). The controls for intratumoral transfection were (1) the injection of NT-polyplex carrying the empty plasmid (pORF) and GCV treatment (n ¼ 9), (2) the injection of an untargeted polyplex carrying the pORF-HSVTK and GCV treatment (n ¼ 3) and (3) the injection of NT-polyplex carrying the pORF-HSVTK without GCV treatment (n ¼ 3). Therefore, the antitumoral effect was dependent on the NT-polyplex specific transfection, HSVTK-coding sequence, and GCV treatment. The systemic transfection of pORF-HSVTK (n ¼ 6) also significantly reduced the tumor growth rate when compared with that from the transfection of the empty plasmid (n ¼ 6), as shown by Figure 6a . At the end of the study, the weight of transfected tumors with pORF-HSVTK was 43% less than that of tumors transfected with the empty plasmid (Figure 6b ). GCV treatment in the absence HSVTK gene transfection did not affect either the growth rate or the weight of tumors, suggesting that the dose used was not toxic (data not shown). These results support the ability of NT-polyplex to cause an antitumoral effect after its injection through the blood stream.
Apoptosis pathway in the effect of the HSVTK gene transfection Cleaved caspase-3, the active form of this protease, 25 is one of the apoptosis executioners involved in the cell death caused by GCV treatment in cells transfected with the HSVTK gene. 26 Accordingly, the GCV treatment increased the immunoreactivity of cleaved caspase-3 in tumoral cells after the intratumoral (Figures 7d-f) or systemic transfection (Figures 7g-i ) of pORF-HSVTK, when compared with the immunoreactivity in matched tumors transfected with the empty plasmid pORF and treated with GCV (Figures 7a-c) . The cleaved caspase-3 immunoreactivity of the tumor cells was found in similar areas where RFP-gene expression was observed. This immunoreactivity pattern was more frequent and intense in the cells of areas near the injection site (in the middle of the tumor) after the intratumoral transfection, whereas this pattern was more abundant in areas of the tumor base after the systemic transfection (data not shown). 27, 28 and therefore these cells are potential targets for transfection when the NTpolyplex is injected through the blood stream. For this purpose, the NT-polyplex containing either the plasmid pORF-Luc coding for luciferase or the empty plasmid pORF was injected into the retro-ophthalmic vein of mice with neuroblastoma tumors. Transgene expression was tested 24-h later in homogenates of the whole organ. The organs selected to measure Luc expression were brain, lung, hearth, liver, pancreas, stomach, gut, colon and kidney (Figure 8 ). The organs that showed a statistical difference when compared to controls were the stomach, gut and colon (n ¼ 4 organs per group). However, the RLUs were about 95% lower than those found in the neuroblastoma tumors in the same animal (Figure 8 ), suggesting that NT-polyplex transfection is more efficient in the tumor cells than in healthy cells of organs known to express the NTSR1. 29 Accordingly, the intestinal tract showed neither histopathological changes nor increased cleaved caspase-3 immunoreactivity after transfection of pORF-HSVTK and GCV treatment (data not shown). To evaluate whether the NT-polypex could lodge in organs even though the transgene expression was not observed, a propidium iodide-labeled NT-polyplex was injected through the blood stream and its biodistribution was determined at 6 and 48 h after the injection. After 6 h, the fluorescent label was found mainly in the liver and spleen, and in lesser amounts in the kidney and lung. Forty-eight hours after the injection, the fluorescent label was not observed suggesting the efficient clearance of the NT-polyplex. The histopathological analysis of the same organs stained with hematoxylin-eosin did not show tissue damage (data not shown), supporting the biosafety of NT-polyplex.
Selectivity of systemic transfection by NT-polyplex NTSR1 is constitutively expressed by neuronal cells and other cells in peripheral tissues
Discussion
Two main conclusions emerge from our study. The first conclusion is that the NT-polyplex is able to specifically transfect NTSR1-bearing cells through the blood stream. The highest transgene expression found in allografted N1E-115 neuroblastoma cells may be caused by the large number of neuroblastoma cells bearing NTSR1. Our measurements with flow cytometry showed that 75±6% of these cells express the receptor in culture (data not shown). Very low transgene expression was detected in the healthy intestinal tract known to express NTSR1 27, 29 and no expression was observed in healthy tissue lacking NTSR1. These results support that the systemic transfection of the NT-polyplex depends on NTSR1, as shown previously using blockage assays with either NT (1 mM) or SR 48692, a synthetic NT competitive antagonist. 1, 3, 5, 8 The specificity was also demonstrated by the negative results of internalization and expression assays after the systemic transfection with an untargeted polyplex (without the ligand NT) or the KP-pDNA complex. The second conclusion is that the specific transfection of a suicide gene into neuroblastoma tumor cells expressing NTSR1 causes a therapeutic effect. Accordingly, the GCV treatment after the transfection of HSVTK gene slowed the tumor growth rate and decreased the volume and weight of transfected tumors. These results were related to a significantly increased number of apoptotic cells in comparison with the control tumors. Therefore, the NTpolyplex represents a new tool for the therapeutic gene delivery to neuroblastoma tumors.
Neuroblastoma is the most frequent extracranial solid tumor originating from the sympathetic nervous system and the first cause of lethality in preschool-age children. 30 Although the neuroblastoma has spontaneous remission or progresses to a differentiated tumor such as ganglioneuroma in children aged less than 1 year, 31 this tumor has aggressive behavior in children older than 1 year. 32 At the time of diagnosis in the latter case, 50% of these patients have already developed metastatic dissemination, and only 20% of these patients have a 5-year survival despite intensive multimodal therapy. 30 To date, treatment with chemotherapy, surgery and radiation therapy has resulted in suboptimal outcomes in patients with advanced disease. 33 Surgery is not effective on the disseminated neuroblastoma and neither are radiation and chemotherapy, which additionally cause severe toxic side effects on healthy tissues. The bad prognosis in the advanced stage of neuroblastoma is the reason to create new therapeutic alternatives more effective, selective and with less side effects than the currently available therapies. The NT-polyplex is an attractive alternative because it is specific, effective, biodegradable and nontoxic. 1, 3, 5, 8, 12 The new advantage of the NT-polyplex shown in this study is the ability to effectively transfect tumoral cells after its administration through the blood stream. This feature will be of great use to target metastasis sites very small or unreachable by surgery. In comparison with chemotherapy or radiotherapy, the benefit of NT-polyplex will be the targeting of tumor cells leaving the healthy cells free of treatment. Although the subcutaneous allograft in nude mice does not reflect the metastatic potential of neuroblastoma tumor, 34 the skin is one of metastatic sites in the stage 4 of neuroblastoma disease. 32 Therefore, if the NT-polyplex is able to transfect the neuroblastoma tumor in the skin (similar to a metastasis), it is plausible to suggest that it would be effective in the treatment of neuroblastoma in stage 4. However, the current trend is to use more realistic tumor models reflecting the growth of advanced neuroblastoma in children, for example, large adrenal gland tumors and multiple small metastatic lesions. 34 The transfection selectivity of the NT-polyplex injected through the blood stream was demonstrated by gene expression in neuroblastoma tumor cells and in cells of the healthy digestive tract because of the presence of NTSR1. 27, 29 However, the gene expression in the neuroblastoma tumor was greater than that of the intestinal tract cells, possibly caused by the difference in the number of NTSR1-bearing cells. From the weak transgene expression in the gastrointestinal tract, neither apoptosis nor histopathological alterations were observed in animals transfected with the HSVTK gene and treated with GCV when compared with controls. The brain that is the organ with the highest density of NTRS1 4, 8, 35 was not transfected by the NT-polyplex injected through the blood stream. This suggests that the NT-polyplex was unable to cross the blood-brain barrier, possibly caused by the inability of NT to penetrate the blood-brain barrier. 10, 28 Because of this feature, the brain will be protected from the NT-polyplex-mediated transfection of cell-death-promoting genes. In addition, NTSR1-bearing cells of healthy peripheral tissues can be protected from the deleterious effects of transgene expression using a neuroblastoma cell-specific promoter such as the NCX promoter 36 or a tumor-selective promoter such as the E2F-1 promoter to confine the therapeutic effect within the tumoral cells. In this work, we used the HSVTK-GCV system because of its efficiency to cause cell death in addition to the bystander effect. 21, 22 This effect includes the transfer of toxic metabolic products of GCV through gap junctions, which are dependent on connexin expression. 38 Other mechanisms related to HSVTK-GCV-mediated bystander effect are fagocytosis of the apoptotic vesicles 39 and the immune response against the tumor. 38 Because of the bystander effect, it has been reported that HSVTK gene transduction of 10-20% of tumor cells in vivo can eliminate the whole tumor. 38, 39 Our results showed that the efficiency of the NT-polyplex transfection in vivo is in the range of 8-12% as determined by RFP gene expression. However, the transfection of the HSVTK gene only caused the reduction of tumor weight and size by 50%. The relatively weak bystander efficiency might be explained by the decrease of functional gap junctions in the allografted N1E-115 cells as has been reported for other neuroblastoma cell lines. 40, 41 Another condition that possibly limits the bystander effect may be the defective immune response mediated by the T-cell linage in the athymic mice used in our tumoral model. 42 The use of the HSVTK-GCV system in human trials to cause the death of tumoral cells has not been efficient. [43] [44] [45] [46] A recently improved HSVTK system based on the TK30 mutant is able to increase the killing efficacy of GCV and the bystander effect on animal models of human tumor cells up to 500-fold. 47 The combination of this system with the expression of exogenous wild-type p53 seems to be optimum for clinical trials of suicide-gene therapy of tumoral cells. 48 Other gene strategies are currently in trial for human use, for example, the restitution of the tumor suppressor gene function, downregulation of oncogenic expression, stimulation of immune response, increase of drug sensitivity and modulation of the tumor angiogenesis. 43 This range of possibilities can be explored with the NT-polyplex. The therapeutic effect of the NT-polyplexmediated gene transfer can be magnified with the combined use of chemotherapy.
In addition to neuroblastoma cells, NTSR1 is expressed in human cancers of breast, lung, colon, prostate and pancreas, and Ewin's sarcomas. [49] [50] [51] [52] Therefore, these types of neoplasia are potential targets for NT-polyplex transfection and open the possibility of exploring new approaches of gene therapy for cancer. 
